Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + daratumumab + low-dose dexamethasone induction followed by ixazomib + daratumumab maintenance in unfit and frail newly diagnosed multiple myeloma
2016-002600-90Phase 2Completed
- Sponsor
- HOVON
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, daratumumab and dexamethasone in multiple myeloma (MM), sponsored by HOVON. Primary endpoint: Overall response rate on induction therapy. Started Mar 2017; status: completed.
02
Drugs
ixazomibdaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-002600-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002600-90.